首页> 外文学位 >Triggered release of vancomycin to bacterial infection sites using pH-sensitive lipid based nanoparticles.
【24h】

Triggered release of vancomycin to bacterial infection sites using pH-sensitive lipid based nanoparticles.

机译:使用基于pH的脂质敏感纳米颗粒触发万古霉素释放到细菌感染部位。

获取原文
获取原文并翻译 | 示例

摘要

The appearance of resistant strains of bacteria in community healthcare facilities is a common occurrence with growing severity. Cases of resistance to beta-lactam drugs such as Methicillin have been shown in Staphylococcus aureus (MRSA) and Staphylococcus epidermis (MRSE), among many others, and these resistances limit therapeutic options. The synthetic glycopeptide antibiotic Vancomycin is considered one of the last lines of defense for these types of resistant infections. Failures in antibiotic therapy at this stage come from inadequate drug concentration at the infected sites, reduction of activity due to local acidity, and toxicity associated with accumulation in non-infected tissue. To solve these issues, an environmentally-responsive lipid-based nanoparticle, or liposome, has been developed to deliver Vancomycin to local infection sites. These liposomes retain their drug contents at physiologic pH, increasing antibiotic circulation time. Additionally, they are selectively triggered to release their drug contents by the external stimulus of decreased pH of local infection sites. Encapsulation of Vancomycin in these liposomes was performed, showing stable retention and release between pH 7.4 and 5.5, respectively. Additionally, demonstration of the enhanced antibiotic activity of the pH-triggered nanoparticles was carried out through Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) studies. From the results, there is promising data suggesting that targeted delivery of Vancomycin using environmentally sensitive liposomes is a candidate for sustained and targeted antibiotic therapy in resistant bacterial infections.
机译:社区医疗机构中细菌耐药菌株的出现是越来越普遍的现象,其严重性也在不断提高。对金黄色葡萄球菌(MRSA)和表皮葡萄球菌(MRSE)等其他药物对β-内酰胺类药物如甲氧西林有耐药性,这些耐药性限制了治疗选择。合成的糖肽抗生素万古霉素被认为是针对这些类型的耐药性感染的最后一道防线。在此阶段抗生素治疗失败的原因是感染部位的药物浓度不足,由于局部酸度导致的活性降低以及与未感染组织中积累有关的毒性。为了解决这些问题,已经开发出一种对环境敏感的基于脂质的纳米颗粒或脂质体,以将万古霉素递送至局部感染部位。这些脂质体可在生理pH值下保留其药物含量,从而延长抗生素循环时间。另外,通过局部感染部位pH降低的外部刺激,选择性地触发它们释放药物含量。进行了万古霉素在这些脂质体中的包封,分别在pH 7.4和5.5之间显示稳定的保留和释放。另外,通过最小抑菌浓度(MIC)和最小杀菌浓度(MBC)研究进行了pH触发的纳米颗粒抗生素活性增强的证明。从结果来看,有希望的数据表明使用对环境敏感的脂质体靶向递送万古霉素是耐药细菌感染中持续和靶向抗生素治疗的候选药物。

著录项

  • 作者

    Holleran, Timothy.;

  • 作者单位

    Rutgers The State University of New Jersey - New Brunswick.;

  • 授予单位 Rutgers The State University of New Jersey - New Brunswick.;
  • 学科 Biomedical engineering.
  • 学位 M.S.
  • 年度 2016
  • 页码 40 p.
  • 总页数 40
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号